Elanco Animal Health Management
Management criteria checks 3/4
Elanco Animal Health's CEO is Jeff Simmons, appointed in Jul 2018, has a tenure of 6.42 years. total yearly compensation is $13.66M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $13.04M. The average tenure of the management team and the board of directors is 6 years and 5.8 years respectively.
Key information
Jeff Simmons
Chief executive officer
US$13.7m
Total compensation
| CEO salary percentage | 8.8% |
| CEO tenure | 6.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 6yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Elanco Animal Health Incorporated's (NYSE:ELAN) Business And Shares Still Trailing The Industry
Dec 12
Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals
Nov 15Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Nov 08Here's Why Elanco Animal Health (NYSE:ELAN) Has A Meaningful Debt Burden
Sep 22Elanco Animal Health Incorporated (NYSE:ELAN) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Sep 01Elanco Animal Health: Positioned For Success
Aug 16Investors Don't See Light At End Of Elanco Animal Health Incorporated's (NYSE:ELAN) Tunnel And Push Stock Down 27%
Jul 11Elanco Animal Health: Pipeline Concerns Appear Overblown
Jun 30Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Jun 06Elanco Animal Health: At Least Fully Valued After Rally
Jun 05Benign Growth For Elanco Animal Health Incorporated (NYSE:ELAN) Underpins Its Share Price
Apr 22Elanco Animal Health (NYSE:ELAN) Seems To Be Using A Lot Of Debt
Feb 24Elanco Animal Health: A Solid Sale Addresses Leverage
Feb 09Elanco Animal Health Incorporated (NYSE:ELAN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 01Elanco Animal Health: Turning More Healthy
Dec 21Elanco Animal Health: Signs Of Stabilization, Amidst Still A Big Debt Pile
Oct 05Elanco Animal Health: Seems Like A Decent Bet Right Now
Jul 25Elanco Animal Health: Robust Results Overshadowed By Persisting Challenges
Jul 14Elanco Q4 2022 Earnings Preview
Feb 20Elanco's Tangible Equity Units: Living With The Worst Case
Dec 13Elanco Q3 2022 Earnings Preview
Nov 07Elanco Animal Health: This 'Sick Dog' Should Recover
Oct 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$205m |
| Jun 30 2024 | n/a | n/a | -US$1b |
| Mar 31 2024 | n/a | n/a | -US$1b |
| Dec 31 2023 | US$14m | US$1m | -US$1b |
| Sep 30 2023 | n/a | n/a | -US$1b |
| Jun 30 2023 | n/a | n/a | -US$113m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$13m | US$1m | -US$78m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$171m |
| Mar 31 2022 | n/a | n/a | -US$371m |
| Dec 31 2021 | US$12m | US$1m | -US$483m |
| Sep 30 2021 | n/a | n/a | -US$698m |
| Jun 30 2021 | n/a | n/a | -US$729m |
| Mar 31 2021 | n/a | n/a | -US$572m |
| Dec 31 2020 | US$9m | US$1m | -US$574m |
| Sep 30 2020 | n/a | n/a | -US$246m |
| Jun 30 2020 | n/a | n/a | -US$101m |
| Mar 31 2020 | n/a | n/a | -US$13m |
| Dec 31 2019 | US$16m | US$1m | US$68m |
| Sep 30 2019 | n/a | n/a | US$94m |
| Jun 30 2019 | n/a | n/a | US$144m |
| Mar 31 2019 | n/a | n/a | US$45m |
| Dec 31 2018 | US$5m | US$775k | US$87m |
| Sep 30 2018 | n/a | n/a | -US$91m |
| Jun 30 2018 | n/a | n/a | -US$172m |
| Mar 31 2018 | n/a | n/a | -US$174m |
| Dec 31 2017 | US$5m | US$688k | -US$311m |
Compensation vs Market: Jeff's total compensation ($USD13.66M) is above average for companies of similar size in the US market ($USD8.04M).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
CEO
Jeff Simmons (57 yo)
6.4yrs
Tenure
US$13,663,169
Compensation
Mr. Jeffrey N. Simmons, also known as Jeff, serves as President and Chief Executive Officer at Elanco Animal Health Incorporated since July 2018 and its Director since September 2018. Mr. Simmons serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$13.66m | 0.23% $ 13.0m | |
| Executive VP & CFO | 6.1yrs | US$3.73m | 0.035% $ 2.0m | |
| Executive Vice President of Elanco International | 6.4yrs | US$2.65m | 0.022% $ 1.3m | |
| Executive Vice President of Research | 3.2yrs | US$3.68m | 0.0097% $ 555.4k | |
| Executive Vice President of Corporate Strategy & Market Development | 1.8yrs | US$2.19m | 0.017% $ 983.1k | |
| Senior VP & Chief Accounting Officer | 6.3yrs | no data | 0.0054% $ 312.8k | |
| Senior VP & Chief Information Officer | no data | no data | no data | |
| Executive Vice President of Human Resources | 5.9yrs | US$2.85m | 0.024% $ 1.4m | |
| Head of Investor Relations | no data | no data | no data | |
| Executive Vice President | 1.9yrs | no data | 0.0048% $ 276.5k | |
| Senior Vice President of Asia | no data | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
6.0yrs
Average Tenure
53yo
Average Age
Experienced Management: ELAN's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$13.66m | 0.23% $ 13.0m | |
| Independent Director | 4yrs | US$330.01k | 0.0061% $ 349.0k | |
| Independent Director | 6.3yrs | US$496.01k | 0.044% $ 2.5m | |
| Independent Director | 4yrs | US$330.01k | 0.0020% $ 116.1k | |
| Independent Chairman | 6.3yrs | US$350.01k | 0.0020% $ 116.1k | |
| Independent Director | 5.6yrs | US$330.01k | 0.00071% $ 40.8k | |
| Independent Director | 5.8yrs | US$330.01k | no data | |
| Independent Director | 5.8yrs | US$346.01k | 0.0084% $ 485.2k | |
| Independent Director | 5.8yrs | US$346.01k | 0.00020% $ 11.5k | |
| Independent Director | 5.8yrs | US$330.01k | no data | |
| Independent Director | 6.3yrs | US$330.01k | 0.0040% $ 227.7k | |
| Independent Director | 6.3yrs | US$355.01k | 0.00065% $ 37.4k |
5.8yrs
Average Tenure
65.5yo
Average Age
Experienced Board: ELAN's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elanco Animal Health Incorporated is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Balaji Prasad | Barclays |